Objective evaluation of potential and currently available pharmaceuticals has been a significant focus of this area. The ORC also examines biologic inhibitors of critical mediators in joint disease, novel protein therapies, gene therapy techniques and mesenchymal stem cell therapies.
Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis
Clinical preparations of platelet-rich plasma (PRP) from autologous blood are created using commercial kits, of which there are numerous options that produce different platelet and growth factor doses.
Gene therapy vectors were used to deliver IL-1ra to joint tissues and appeared to significantly increase protein production in equine joint tissues.
Age does not appear to significantly influence the efficacy of gene transduction using scAAV in synoviocytes and chondrocytes in horses.
While extracorporeal shock wave therapy (ESWT) has been shown to enhance the therapeutic potential of certain cell types, its effect on equine mesenchymal stem cells (MSCs) is not known.
Intra-articular corticosteroids are potent anti-inflammatory agents with prolonged effectiveness for traumatic joint disease in the horse. Generalizations about harmful effects of intra-articular corticosteroids are inappropriate, and research has defined differences in beneficial and deleterious effects.
Gene transduction of chondrocyte and synovial monolayer is significantly different than cartilage and synovial explants and this study highlights the necessity to test gene therapeutic tissue in situ.
The field of mesenchymal stem cell research is an ever evolving science and much work is still needed in the clinical application of this treatment modality.